Associate Professor, Internal Medicine, University of Michigan Medical School
Oncology
Dr. Anne F. Schott, MD
|
|
Give Review
Anne F. Schott is an expert in the field of Oncology. He went to University of South Alabama College of Medicine. University of South Alabama College of Medicine is ranked 83/35 in Research/PrimaryCare. He received awards:"CMS Meaningful Use Stage 1 Certification". Anne Schott is also a published doctor. He has 31 publication published. The most recent publication is: Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Doctor Anne F. Schott, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Clinical predictors of long-term survival in HER2-positive metastatic breast Cancer.
- ESR1 mutations in circulating plasma tumor DNA from metastatic breast Cancer patients.
- Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor Positive Breast Cancer.
- Assessment of PIK3CA Mutations in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Clinical Validity but Not Utility.
- Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500.
- Image registration for quantitative parametric response mapping of Cancer treatment response.
- Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor-Treated Women with Early-Stage Breast Cancer.
- Prediction of Post-Chemotherapy Ovarian Function Using Markers of Ovarian Reserve.
- Activating ESR1 mutations in hormone-resistant metastatic breast Cancer.
- Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial.
- Predictors of recovery of Ovarian function during aromatase inhibitor therapy.
- Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors.
- Defining the benefits of neoadjuvant chemotherapy for breast Cancer.
- Evaluation of an Automatic Registration-Based Algorithm for Direct Measurement of Volume Change in Tumors.
- Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms.
- Spatial registration of temporally separated whole Breast 3D ultrasound images.
- Predictors and temporal trends of adjuvant aromatase inhibitor use in breast Cancer.
- Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
- Axillary staging prior to neoadjuvant chemotherapy for breast Cancer: predictors of recurrence.
- Monitoring serial changes in circulating human breast Cancer cells in murine xenograft models.
- Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast Cancer.
- Prospective early response imaging biomarker for neoadjuvant breast Cancer chemotherapy.
- Combination vinorelbine and capecitabine for metastatic breast Cancer using a non-body surface area dosing scheme.
- Clinical and radiologic assessments to predict breast Cancer pathologic complete response to neoadjuvant chemotherapy.
- Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.
- Sonographic evaluation of early-stage breast Cancers that undergo neoadjuvant chemotherapy.
- Pathologic features of breast Cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis.
- A phase I dose escalation trial of gemcitabine with radiotherapy for breast Cancer in the treatment of unresectable chest wall recurrences.
- Sentinel node biopsy prior to neoadjuvant chemotherapy.
- Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
Schools
University of South Alabama College of Medicine
University Of Mi Hosps and Health Ctrs
University Of Va Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Michigan Hospitals and Health Centers -
University of Virginia -
University of South Alabama College of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1720164692 | |
| NPPES Provider LastName | SCHOTT | |
| NPPES Provider FirstName | ANNE | |
| NPPES Provider ZIPCode | 481095916 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 375.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720164692 |
| Last Name Of The Provider | SCHOTT |
| First Name Of The Provider | ANNE |
| View All |
Similar Doctors
|
|
Dr. Max S. Wicha, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mark M. Zalupski, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Kathleen A. Cooney, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Norah L. Henry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monika L. Burness, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Moshe Talpaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manuel Valdivieso, MD |
|
|
Dr. Jennifer J. Griggs, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Patrick J. Hu, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|